113
Views
2
CrossRef citations to date
0
Altmetric
Case Series

Real-World Experience on Omalizumab Treatment for Patients with Normocomplementemic Urticarial Vasculitis

, , , ORCID Icon, , , ORCID Icon & ORCID Icon show all
Pages 433-437 | Published online: 23 Apr 2021

Figures & data

Table 1 Clinical Features and Treatment History of Patients with Normocomplementemic Urticarial Vasculitis Before Omalizumab Treatment

Table 2 Laboratory Features and Omalizumab Treatment Protocol of Patients with Normocomplementemic Urticarial Vasculitis

Figure 1 Disease activity and quality of life of patients with normocomplementemic urticarial vasculitis during the 24-week study period. (A) Total UVAS score, (B) UVAS wheals score, (C) UVAS pruritus score, (D) UVAS residual skin pigmentation score, (E) UVAS arthralgia score, (F) UVAS general symptoms score, and (G) DLQI.

Abbreviations: UVAS, urticarial vasculitis activity score; DLQI, Dermatology Life Quality Index.
Figure 1 Disease activity and quality of life of patients with normocomplementemic urticarial vasculitis during the 24-week study period. (A) Total UVAS score, (B) UVAS wheals score, (C) UVAS pruritus score, (D) UVAS residual skin pigmentation score, (E) UVAS arthralgia score, (F) UVAS general symptoms score, and (G) DLQI.